Key Record Dates
| ClinicalTrials.gov Identifier: | NCT02390427 |
|---|---|
| Brief Title: | Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer |
| First Submitted : | March 11, 2015 |
| First Submitted that Met QC Criteria : | March 11, 2015 |
| First Posted : | March 17, 2015 (Estimate) |
| Last Update Submitted that Met QC Criteria : | February 26, 2024 |
| Last Update Posted : | February 28, 2024 |